Johnson & Johnson’s Spravato Surges Toward Blockbuster Status
Last reviewed and updated: June 25, 2026.
Key Takeaways
| Q2 2025 revenue | $414M (+53% YoY); on pace for ~$1.7B full-year 2025; fastest-growing psychiatric drug in U.S. |
| Insurance coverage | Covered for TRD + MDD with suicidal ideation; J&J patient savings program caps co-pays at $10/session for eligible commercial patients |
| vs IV ketamine | Spravato: FDA-approved, often covered, nasal spray; IV ketamine: off-label, out-of-pocket, racemic mixture |
| Protocol | Induction 2x/week ×4 weeks; consolidation 1x/week ×4 weeks; maintenance 1–2x/month ongoing |
| Competition ahead | Definium DT120 (LSD, Phase 3 positive June 2026) + Compass psilocybin (NDA in process) enter “fast-acting antidepressant” market |
Johnson & Johnson’s depression nasal spray Spravato continues its impressive growth trajectory, generating $414 million in Q2 2025 revenue. This represents a remarkable 53% increase from the previous year, positioning the drug to reach approximately $1.7 billion in annual sales.
Find a REMS-certified Spravato clinic near you in our verified provider directory.
Do you work in the ketamine industry? Save thousands on overhead and other fees by joining the first GPO for ketamine clinics and practitioners. There’s no cost to join and zero obligations. Sign up here!
| Key Metrics | Q2 2025 | Q2 2024 | Growth |
|---|---|---|---|
| Global Revenue | $414M | $271M | 53% |
| US Sales | $366M | $226M | 61% |
| International Sales | $50M | $44M | 13% |
| Six-Month Revenue | $734M | $496M | 48% |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Driving Forces Behind the Growth
The accelerated sales reflected “increased physician and patient confidence,” according to Jessica Moore, Johnson & Johnson’s head of investor relations. Doctors have become more comfortable prescribing Spravato after seeing real-world benefits in their patients over five years of data.
The growth coincides with expanded treatment options. The FDA approved Spravato as a standalone therapy for treatment-resistant depression in January 2025, marking the first-ever monotherapy option for this difficult-to-treat condition. Previously, patients required concurrent oral antidepressants.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Market Position and Future Outlook
Spravato generated $780 million in sales during the first nine months of 2024 as doctors grew more comfortable using it. Johnson & Johnson maintains ambitious expectations, projecting annual sales to reach between $1 billion and $5 billion.
Jefferies analyst Andrew Tsai noted that “Spravato’s strong sales trajectory supports the notion psychedelics can become commercially viable for mental health”. This momentum comes at a crucial time as Johnson & Johnson prepares for patent expiration pressures on other key products.
Beyond Traditional Treatments
The drug is administered at 3,000 certified outpatient treatment centers across the United States. Dr. Gregory Mattingly, who has treated over 6,000 patients with Spravato, emphasized that “for the first time ever, we now have an option that gives patients freedom” from traditional antidepressant side effects.
The robust growth underscores Spravato’s transformation from experimental treatment to mainstream therapeutic option, validating Johnson & Johnson’s investment in innovative mental health solutions.
Spravato in 2025–2026: The Trajectory Toward Becoming Psychiatry’s First Billion-Dollar Psychedelic
The article above reflects Spravato’s Q2 2025 performance — $414 million in quarterly revenue, 53% year-over-year growth. That trajectory continued through the remainder of 2025. Johnson & Johnson projected Spravato revenue would surpass $1.7 billion for the full year 2025, based on first-half results. The drug’s growth is being driven by both expanding insurance coverage for its FDA-approved indications (treatment-resistant depression and MDD with suicidal ideation) and by increasing prescriber awareness as psychiatrists become more comfortable with the REMS requirements and supervised administration protocol.
What is driving Spravato’s growth? Three factors stand out: (1) Insurance coverage expansion — as prior authorization processes streamline and more insurance plans include Spravato on formulary for TRD, patient access has improved dramatically. In early years, the REMS requirement (patients must take Spravato in a certified medical setting and be monitored for 2 hours) created logistical barriers; practices have now built these protocols into their workflows. (2) Competitive positioning vs. IV ketamine — Spravato offers something IV ketamine cannot: insurance coverage and FDA approval. Patients who previously paid $4,000–$8,000 out-of-pocket for IV ketamine can now access esketamine for much lower co-pays or sometimes free with patient assistance. (3) MDD with suicidal ideation indication — the 2020 label expansion to include major depressive disorder with active suicidal ideation or behavior significantly broadened the eligible patient population beyond treatment-resistant depression alone.
The pipeline beyond Spravato. J&J has maintained investment in the broader ketamine/NMDA space. Meanwhile, the ketamine clinical landscape is evolving: generic esketamine is not yet available (patent protection), but oral ketamine and compounded racemic ketamine remain accessible off-label through ketamine clinics and some psychiatry practices. The space is also seeing new entrants: Definium Therapeutics (formerly MindMed) announced positive Phase 3 results for DT120 (an oral LSD formulation) for MDD in June 2026 — the first potential approval of a psychedelic-derived drug that would directly compete in the “fast-acting antidepressant” market where Spravato currently has no competition among approved drugs.
Spravato vs. IV ketamine in 2025: which is right for patients? The choice depends on insurance status and individual clinical factors. For patients with qualifying insurance, Spravato is often the lower-cost and lower-barrier option — covered, no IV, administered at a clinic psychiatrist’s office. For patients paying out-of-pocket or who have not responded to Spravato, IV ketamine clinics (which use the full racemic mixture vs. Spravato’s S-enantiomer only) offer an alternative. Some clinicians argue the full racemic mixture has different properties; the evidence base is not yet definitive. Both remain effective for a substantial proportion of treatment-resistant depression patients.
Frequently Asked Questions
How much does Spravato cost with insurance?
With insurance coverage for its FDA-approved indications (TRD and MDD with suicidal ideation), Spravato can be dramatically less expensive than IV ketamine. Johnson & Johnson offers a patient savings program that caps commercial insurance co-pays at $10 per treatment session for eligible patients. Medicare and Medicaid coverage exists but varies by plan — some cover Spravato for TRD under Part D or managed care. For uninsured patients, the list price is approximately $800–$900 per session, making it substantially more expensive than IV ketamine on a per-session basis (though the overall cost depends on how many sessions are needed). The REMS requirement means all sessions must occur in a certified medical setting.
What is the difference between Spravato and IV ketamine?
Spravato is esketamine — the S-enantiomer of ketamine — delivered as a nasal spray in a certified clinical setting under the FDA’s REMS program. It is FDA-approved for treatment-resistant depression and MDD with active suicidal ideation. IV ketamine uses the full racemic mixture (both R- and S-ketamine) and is administered intravenously. Key practical differences: Spravato is FDA-approved and often insurance-covered; IV ketamine is off-label for psychiatric use and almost always out-of-pocket. For dosing: patients self-administer Spravato nasally while supervised; IV ketamine requires IV line placement. Both involve clinic visits with monitoring time. Some clinicians believe the full racemic mixture in IV ketamine produces different effects than Spravato’s S-enantiomer alone, but direct comparative efficacy data is limited.
How many Spravato sessions are required?
The FDA-approved protocol calls for twice-weekly sessions for 4 weeks (induction phase), followed by once-weekly sessions for 4 weeks (consolidation), then maintenance dosing every 1–2 weeks as needed. Response is typically assessed at week 4; non-responders may be discontinued. Many patients experience initial relief within the first 1–2 sessions. Long-term responders often continue maintenance dosing indefinitely, similar to how oral antidepressants are maintained. Most insurance plans cover the induction and consolidation phases; maintenance coverage may require ongoing prior authorization demonstrating continued response.
Is Spravato addictive?
Ketamine has known addiction potential, particularly with frequent unsupervised high-dose use. The Spravato REMS program is specifically designed to minimize this risk: patients cannot take the drug home, all sessions occur in certified medical settings, patients are monitored for 2 hours post-dose, and dissociative symptoms and blood pressure are assessed at each visit. In clinical trials of Spravato, the rate of new substance use disorders attributable to esketamine was low. The REMS requirement is more stringent than most psychiatric medications precisely because of this risk consideration. For patients with active substance use disorders (particularly dissociative drugs), Spravato is typically contraindicated or used with extra caution.
